Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Lifesci Capital

Lifesci Capital reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research note released on Monday morning, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

Several other equities analysts also recently commented on CATX. Oppenheimer restated an outperform rating and issued a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. B. Riley boosted their target price on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a buy rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at 1.76 on Monday. Perspective Therapeutics has a fifty-two week low of 0.21 and a fifty-two week high of 1.90. The company has a market capitalization of $1.03 billion, a P/E ratio of -17.60 and a beta of 1.43. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. acquired a new position in Perspective Therapeutics in the third quarter valued at $731,000. HighTower Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth about $314,000. Bank of New York Mellon Corp purchased a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at about $42,000. RIA Advisory Group LLC boosted its position in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the period. Finally, Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after buying an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.